Viyash Scientific (512529) Q4 01/02 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 01/02 earnings summary
29 Oct, 2026Executive summary
FY ended Mar. 31, 2002 recorded a loss after tax of Rs 97,462, compared with Rs 104,545 in FY01; no dividend was recommended.
Total assets were Rs 56.06m, including Rs 55.57m in loans and advances.
Financial highlights
Total revenue was reported as NIL; expenses were Rs 97,462 and loss before and after tax was Rs 97,462.
Loss narrowed from Rs 104,545 in FY01 to Rs 97,462 in FY02; closing accumulated profit balance was Rs 1.899m.
Administrative and other expenses were Rs 97,462 versus Rs 104,553 in FY01, including Rs 57,877 of share issue expense amortization.
Key financial ratios and metrics
Earnings per share and dividend rate were both reported as NIL; no dividend was recommended for FY02.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Viyash Scientific
- FY1997-98 profit was Rs 36,882; earnings were retained and Rs 10 crore borrowing authority proposed.512529
Q4 97/98 - Investment-sale gains lifted FY99 PAT to ₹1.653m; earnings were retained and no dividend recommended.512529Q4 98/99
- FY03 loss widened as Rs 54.50m in loans and advances dominated the balance sheet.512529Q4 02/03
- ₹295.51 lakh FY04 net profit; growth guidance exceeded 50% post-amalgamation.512529Q4 03/04
- FY05 profit rose as capacity expansion and new markets became central priorities.512529Q4 04/05
- FY06 growth and new capacity supported expansion, while rising input costs remained a key risk.512529Q4 05/06
- Sales climbed 23%; adjusted PAT rose 32% as R&D and veterinary APIs set the growth agenda.512529Q4 06/07
- Transchem expanded the business as currency pressure and higher costs squeezed profit.512529Q4 07/08
- Standalone profit grew, but consolidation swung to a ₹1,466 lakh net loss.512529Q4 08/09